Morning Trend | FOSUN PHARMA tests support, capital flow in the pharmaceutical sector becomes the focus?

FOSUN PHARMA (2196.HK) has recently faced overall pressure on its stock price, continuing its downward adjustment trend. The daily K-line has formed multiple small bearish candles, and trading volume has continued to shrink, indicating that market funds are cautiously observing. Recently, the 5-day and 10-day moving averages have been continuously crossing downward, and the MACD indicator remains in a bearish crossover, showing a clear short-term weak pattern. Fundamentally, FOSUN PHARMA's core business includes generic drugs, innovative drugs, and medical services, with strong product pipeline reserves and R&D capabilities. However, due to the constraints of medical insurance cost control, industry centralized procurement, and slowing drug sales growth, the company's profitability is expected to fluctuate in the short term. The Hong Kong stock market's pharmaceutical sector is generally showing a trend of deleveraging and institutional outflows, with FOSUN PHARMA, as a representative stock in the sector, being significantly dragged down. From a technical perspective, FOSUN PHARMA is approaching the HKD 20 support level, where historically, the main funds have shown strong intervention. If trading volume warms up during today's session and there are signs of large orders accumulating, it may lead to a phase of rebound driven by capital inflow, with an initial target looking towards HKD 21.5 and the dense area of moving averages above. If the volume continues to shrink while probing lower, the HKD 20 support may be difficult to maintain, with lower support needing to be observed in the HKD 18-19 range. In terms of investment advice, it is essential to closely monitor intraday capital movements and sector fund flows. Aggressive investors may take small positions to bet on a rebound from oversold conditions but should set strict stop-loss orders; conservative investors should mainly observe and wait for clear volume increases and right-side signals. Overall, the pharmaceutical sector is still primarily focused on existing stock games in the short term, with differentiation potentially intensifying, requiring a comprehensive judgment that combines both fundamentals and technical aspects